Using multiple targeted therapies in oncology: Considerations for use, and progress to date in breast cancer

Drugs

Volumn 73, Issue 6, 2013, Pages 505-515

  Kelly, Catherine M ^a   Buzdar, Aman U ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; FULVESTRANT; LAPATINIB; LETROZOLE; PACLITAXEL; PERTUZUMAB; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; META ANALYSIS; MOLECULARLY TARGETED THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MEDICAL ONCOLOGY; RECEPTOR, ERBB-2; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 84878304582     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0044-0     Document Type: Article

References (41)

1. DA Berry KA Cronin SK Plevritis, et al. 2005 Effect of screening and adjuvant therapy on mortality from breast cancer N Engl J Med 353 1784 1792 16251534 10.1056/NEJMoa050518 1:CAS:528:DC%2BD2MXhtFKrtLbN
2. PE Goss JN Ingle JE Ales-Martinez, et al. 2011 Exemestane for breast-cancer prevention in postmenopausal women N Engl J Med 364 2381 2391 21639806 10.1056/NEJMoa1103507 1:CAS:528:DC%2BC3MXotVCkurY%3D
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-717.
4. J Cuzick I Sestak M Baum, et al. 2010 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial Lancet Oncol 11 1135 1141 21087898 10.1016/S1470-2045(10)70257-6 1:CAS:528:DC%2BC3cXhsVyhsLnF
5. J Cuzick T Powles U Veronesi, et al. 2003 Overview of the main outcomes in breast-cancer prevention trials Lancet 361 296 300 12559863 10.1016/S0140-6736(03)12342-2 1:STN:280:DC%2BD3s%2FltVCmsA%3D%3D
6. MJ Piccart-Gebhart M Procter B Leyland-Jones, et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 16236737 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L
7. EH Romond EA Perez J Bryant, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F
8. D Slamon W Eiermann N Robert, et al. 2011 Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 1273 1283 21991949 10.1056/NEJMoa0910383 1:CAS:528:DC%2BC3MXht12mtLvN
9. AG Patel SB De Lorenzo KS Flatten GG Poirier SH Kaufmann 2012 Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro Clin Cancer Res 18 1655 1662 22291137 10.1158/1078-0432.CCR-11-2890 1:CAS:528:DC%2BC38XktVynu7k%3D
10. H Ledford 2012 Drug candidates derailed in case of mistaken identity Nature 483 519 22460874 10.1038/483519a 1:CAS:528:DC%2BC38Xks12huro%3D
11. J Baselga J Cortes SB Kim, et al. 2012 Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 109 119 22149875 10.1056/NEJMoa1113216 1:CAS:528:DC%2BC38XhtFSlt7Y%3D
12. J Baselga M Campone M Piccart, et al. 2012 Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 520 529 22149876 10.1056/NEJMoa1109653 1:CAS:528:DC%2BC38XisVKqsrs%3D
13. L Gianni T Pienkowski YH Im, et al. 2012 Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 25 32 22153890 10.1016/S1470-2045(11)70336-9 1:CAS:528:DC%2BC38XkslSmsQ%3D%3D
14. AD Barker CC Sigman GJ Kelloff NM Hylton DA Berry LJ Esserman 2009 I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy Clin Pharmacol Ther 86 97 100 19440188 10.1038/clpt.2009.68 1:STN:280:DC%2BD1Mvis1Gjsg%3D%3D
15. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med. 2012;366(26):2438-41. doi: 10.1056/NEJmp1205737.
16. AF Schott DF Hayes 2012 Defining the benefits of neoadjuvant chemotherapy for breast cancer J Clin Oncol 30 1747 1749 22508810 10.1200/JCO.2011.41.3161
17. A Buzdar J Douma N Davidson, et al. 2001 Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate J Clin Oncol 19 3357 3366 11454883 1:CAS:528:DC%2BD3MXlvVamsro%3D
18. AU Buzdar 2001 Endocrine therapy in the treatment of metastatic breast cancer Semin Oncol 28 291 304 11402439 10.1016/S0093-7754(01)90122-8 1:CAS:528:DC%2BD3MXltFWksrw%3D
19. J Baselga V Semiglazov P van Dam, et al. 2009 Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer J Clin Oncol 27 2630 2637 19380449 10.1200/JCO.2008.18.8391 1:CAS:528:DC%2BD1MXnslWit7s%3D
20. T Bachelot C Bourgier C Cropet, et al. 2012 Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study J Clin Oncol 30 2718 2724 22565002 10.1200/JCO.2011.39.0708 1:CAS:528: DC%2BC38XhsFertrzN
21. RL Yamnik A Digilova DC Davis ZN Brodt CJ Murphy MK Holz 2009 S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation J Biol Chem 284 6361 6369 19112174 10.1074/jbc.M807532200 1:CAS:528:DC%2BD1MXisVSku7s%3D
22. A Boulay J Rudloff J Ye, et al. 2005 Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer Clin Cancer Res 11 5319 5328 16033851 10.1158/1078-0432.CCR-04-2402 1:CAS:528:DC%2BD2MXmt12qu70%3D
23. TW Miller JM Balko CL Arteaga 2011 Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer J Clin Oncol 29 4452 4461 22010023 10.1200/JCO.2010.34.4879 1:CAS:528:DC%2BC38Xns1Sgug%3D%3D
24. Finn RS, Crown JP, Lang I. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer. (BC)CTRC-AACR San Antonio Breast Cancer Symposium 4-8 2012, San Antonio, TX. Abstract S1-6.
25. A Howell J Cuzick M Baum, et al. 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60 62 15639680 10.1016/S0140-6736(05) 74803-0 1:STN:280:DC%2BD2M%2FhsVartA%3D%3D
26. IE Smith M Dowsett SR Ebbs, et al. 2005 Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23 5108 5116 15998903 10.1200/JCO.2005.04.005 1:CAS:528:DC%2BD2MXpsFWmtLY%3D
27. LF Macedo GJ Sabnis OG Goloubeva A Brodie 2008 Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model Cancer Res 68 3516 3522 18451180 10.1158/0008-5472.CAN-07-6807 1:CAS:528:DC%2BD1cXltlSltLs%3D
28. J Bergh PE Jonsson EK Lidbrink, et al. 2012 FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer J Clin Oncol 30 1919 1925 22370325 10.1200/JCO.2011.38.1095 1:CAS:528:DC%2BC38XpvVSgsbg%3D
29. RS Mehta WE Barlow KS Albain, et al. 2012 Combination anastrozole and fulvestrant in metastatic breast cancer N Engl J Med 367 435 444 22853014 10.1056/NEJMoa1201622 1:CAS:528:DC%2BC38XhtlSltrbF
30. A Di Leo G Jerusalem L Petruzelka, et al. 2010 Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer J Clin Oncol 28 4594 4600 20855825 10.1200/JCO.2010.28.8415
31. Di Leo A, Jerusalem G, Petruzelka L. Final analysis of overall survival for the phase III CONFIRM trial: Fulvestrant 500 mg versus 250 mg. San Antonio Breast Cancer Symposium Dec 4-8, San Antonio, TX. Abstract S1-4.
32. Johnston S, Kilburn LS, Ellis P, Cameron D, Dodwell D, Howell A, Im YH, Coombes G, Dowsett M, Bliss JM. Fulvestrant alone or with concomitant anastrozole vs exemestane following progression on non-steroidal aromatase inhibitor-first results of the SoFEa trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747). Eur J Cancer. 2012;48(Suppl 3):S2 (Late breaking abstract).
33. International Breast Cancer Study Group. Suppression of ovarian function and either tamoxifen or exemestane with or without chemotherapy in treating premenopausal women with resected breast cancer. In: ClinicalTrials.gov: National Library of Medicine (US). http://clinicaltrials.gov/ct2/show/ NCT00066807?term=The+Suppression+of+Ovarian+Function+Trial&rank=2. NLM Identifier:NCT00066807. Accessed 18 June 2012.
34. C Vogel MA Cobleigh D Tripathy, et al. 2001 First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report Eur J Cancer 37 Suppl 1 S25 S29 11167088 10.1016/S0959-8049(00)00405-6 1:CAS:528:DC%2BD3MXpsVeksA%3D%3D
35. H Joensuu P Bono V Kataja, et al. 2009 Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial J Clin Oncol 27 5685 5692 19884557 10.1200/JCO.2008.21.4577 1:CAS:528:DC%2BC3cXhtVWisb8%3D
36. J Baselga KA Gelmon S Verma, et al. 2010 Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy J Clin Oncol 28 1138 1144 20124182 10.1200/JCO.2009.24.2024 1:CAS:528: DC%2BC3cXktF2ltLg%3D
37. CC Portera JM Walshe DR Rosing, et al. 2008 Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer Clin Cancer Res 14 2710 2716 18451236 10.1158/1078-0432.CCR-07-4636 1:CAS:528: DC%2BD1cXlsV2qtLc%3D
38. J Baselga I Bradbury H Eidtmann, et al. 2012 Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet 379 633 640 22257673 10.1016/S0140-6736(11) 61847-3 1:CAS:528:DC%2BC38XisFWjsrs%3D
39. V Guarneri A Frassoldati A Bottini, et al. 2012 Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study J Clin Oncol 30 1989 1995 22493419 10.1200/JCO.2011.39.0823 1:CAS:528:DC%2BC38XpvVSgtrs%3D
40. Robidoux A, Tang G, Rastogi P, Geyer CE, Azar CA. Evaluation of lapatinib as a component of neoadjuvant therapy for HER21 operable breast cancer: NSABP protocol B-41. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, June 1-5. 2012. J Clin Oncol. 2012;30 (suppl; abstr LBA506).
41. K Miller M Wang J Gralow, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 18160686 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D